Venture Capital

Workplace culture strategist Jennifer Moss joins a list of legends as Toastmasters International’s 2026 Golden Gavel honoree. Here’s why her work matters now.

A SPAC deal aims to bring Hong Kong's AI-driven waste sorter Rongcheng public, highlighting a major bet on the future of green technology and recycling.

Dartmouth-based GSTS secures ACOA funding to expand its OCIANA AI platform, enhancing maritime security for NATO and optimizing global supply chains.

With a major Series B financing, Crossbow advances its TCR-mimetic therapies, aiming to unlock a new frontier in the fight against a broad range of cancers.

Dr. Toyin Ajayi's board appointment signals a major strategic move to integrate nutrition into healthcare for America's most vulnerable populations.

As AI pushes grids to the brink, Exowatt opens a new Texas facility to deploy its modular, clean power solutions, aiming to reshape energy infrastructure.

The rapidly growing clean wine brand Avaline is placing new sales leaders in key cities, signaling an aggressive push for national market dominance.

With new execs from Grail and Eli Lilly, ClearNote Health signals a major push to get its AI-powered cancer detection tests through trials and into the market.

A new AI platform lets developers search for land by what they want to build, bypassing complex zoning codes and promising to accelerate construction.

An Israeli deep-tech firm has launched from stealth with a novel AI platform to solve the energy bottleneck strangling the global AI revolution.

Cingulate Inc. faces a critical FDA decision for its novel ADHD drug, but manufacturing queries and a tight cash runway create a high-stakes countdown.

Swiss firm H55's flight-proven batteries are fast-tracking a new hybrid-electric regional aircraft demonstrator, promising a 30% leap in fuel efficiency.

Semiconductor firm Guerrilla RF is leveraging off-the-shelf parts to accelerate next-gen satellite tech, from military comms to direct-to-cell service.

With veteran leader Brian McKelligon at the helm, Infinity Bio aims to commercialize its powerful MIPSA platform and redefine precision medicine.

China is rolling out a 10-day visa-free transit policy and promoting immersive cultural tours. But can it overcome geopolitical headwinds to revive tourism?

The controversial safety app Citizen is in 15 new cities. It promises real-time alerts but brings a history of privacy concerns and vigilantism fears.

With a massive $68.7M seed round and novel T-cell engager tech, Shanghai's Excalipoint is pioneering a new model for rapid drug development.

Operator of China's BOSS Zhipin announces a major dividend and buyback plan, signaling deep confidence in its market dominance and future profitability.

With a new context-aware AI and $45M from General Catalyst, the PowerPoint rival aims to automate design and conquer the global presentation market.

With a new CEO and Chair, IsomAb is advancing a disease-modifying drug for 9 million angina patients, eyeing a major Series A fundraise.